Corvus Pharmaceuticals (CRVS) Free Cash Flow (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Free Cash Flow of -$10.5 million for Q1 2026, down 26.1% year-over-year from -$14.2 million in Q1 2025, and down 20.23% quarter-over-quarter from -$8.7 million in Q4 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Free Cash Flow (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$10.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 26.1% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$34.6 million (down 19.9% YoY), while the FY2025 annual figure was -$32.5 million, down 27.53% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$10.5 million, down from -$8.7 million in the prior quarter.
- The five-year high for Free Cash Flow was -$4.9 million in Q1 2024, with the low at -$10.5 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$6.4 million (2022), against an average of -$7.0 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow surged 48.48% in 2022, then tumbled 81.11% in 2024.
- Corvus Pharmaceuticals' Free Cash Flow stood at -$7.8 million in 2022, then surged by 33.79% to -$5.2 million in 2023, then sank by 81.11% to -$9.4 million in 2024, then climbed by 6.99% to -$8.7 million in 2025, then slipped by 20.23% to -$10.5 million in 2026.
- Business Quant data shows CRVS's Free Cash Flow at -$10.5 million in Q1 2026, -$8.7 million in Q4 2025, and -$9.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | -15.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.98 Mn |
| Mar 31, 2026 | -10.47 Mn |
| Dec 31, 2025 | -9.10 Mn |
| Sep 30, 2025 | -9.48 Mn |
| Jun 30, 2025 | -5.69 Mn |
| Mar 31, 2025 | -8.18 Mn |
| Dec 31, 2024 | -9.36 Mn |
| Sep 30, 2024 | -6.03 Mn |
| Jun 30, 2024 | -5.19 Mn |
| Mar 31, 2024 | -4.87 Mn |
| Dec 31, 2023 | -4.07 Mn |
| Sep 30, 2023 | -5.43 Mn |
| Jun 30, 2023 | -5.22 Mn |
| Mar 31, 2023 | -8.15 Mn |
| Dec 31, 2022 | -6.31 Mn |
| Sep 30, 2022 | -7.19 Mn |
| Jun 30, 2022 | -6.12 Mn |
| Mar 31, 2022 | -6.42 Mn |
| Dec 31, 2021 | -6.81 Mn |
| Sep 30, 2021 | -8.39 Mn |